Five Prime Therapeutics Stock Analysis (NASDAQ:FPRX)
Five Prime Therapeutics Analysis Video
View Five Prime Therapeutics stock analysis video. This is our FPRX analyst opinion covering the buy and sell arguments for FPRX stock.
Five Prime Therapeutics Inc Stock Rating (3.3/5)
Our Five Prime Therapeutics stock opinion is based on fundamentals of the company. This Five Prime Therapeutics stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.
Should you buy FPRX stock?
- The TTM operating margin was good at 69% for Five Prime Therapeutics.
- FPRX stock is trading at an earnings multiple of 5.2 which is better than the industry average of 22.4.
- When compared with the Medical-Biomed-Genetics industry average PS ratio of 4.6, the price-to-sales ratio of 3.3 for FPRX stock is attractive.
- The LTM ROE of 68.9% for Five Prime Therapeutics is attractive.
Should you sell FPRX stock?
- The company has negative Free Cash Flows (FCF), with a negative FCF margin of -238.5%.